Science News

Adaptive biokinetic modelling of iodine-131 in thyroid cancer treatments: implications on individualized internal dosimetry.

A new interesting article has been published in J Radiol Prot. 2018 Sep 26. doi: 10.1088/1361-6498/aae44e. and titled:

Adaptive biokinetic modelling of iodine-131 in thyroid cancer treatments: implications on individualized internal dosimetry.

Authors of this article are:
Guiu-Souto J Neira Castro S Sánchez-García M López-Pouso O Pombar M Pardo-Montero J.

A summary of the article is shown below:
Nowadays therapies involving radioiodine (I-131) represents 84% of the total metabolic treatments in Europe, according to the last report of the European Association of Nuclear Medicine (EANM) in relation to treatment planning for molecular radiotherapy. Last recommendations of the European Council, i.e. 2013/59/Euroatom, mandates that metabolic treatments should be planned according to the radiation doses delivered to individual patients, analogous to external beam radiotherapy. In this work, we present a novel biokinetic model for I-131 that allows obtaining realistic activity distributions for particular patients with thyroid cancer in absence of metastasis. Other models existing in the literature present either too simple metabolic description to obtain realistic results or a too complex one for adapting the model to individual patients. The individualization of activity distribution is obtained by an optimization method that adjusts our model to a set of experimental measurements. Significant differences in terms of absorbed doses are observed between our model and the standard generalist models, especially in terms of red marrow absorbed dose.

Check out the article’s website on Pubmed for more information:



This article is a good source of information and a good way to become familiar with topics such as: Internal Dosimetry;Metabolic Radiotherapy;Nuclear Medicine;Thyroid Cancer.

Categories: Science News